42Z.F REVOLUTION MED. DL-0001
- Market cap
- EUR 35.3B
- P/E
- -
- P/B
- 17.94x
- ROE
- -83.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 42Z.F undervalued?
Graham numberThe Graham number of REVOLUTION MED. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
REVOLUTION MED. DL-0001 fundamental analysis
No fundamental analysis for REVOLUTION MED. DL-0001 yet.
REVOLUTION MED. DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About REVOLUTION MED. DL-0001
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-a…
Full company profileREVOLUTION MED. DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
REVOLUTION MED. DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 29.4M | 35.4M | 11.6M | 0.00 | 0.00 | 263M |
| Operating Income | -188M | -258M | -487M | -690M | -1.18B | -1.76B |
| EBITDA | - | -249M | -431M | -589M | -1.09B | -1.90B |
| Net Income | -187M | -249M | -436M | -600M | -1.13B | -2.01B |
| EPS | -2.52 | -2.75 | -2.65 | -3.23 | -5.74 | -9.28 |
| Balance Sheet | ||||||
| Total Assets | 738M | 812M | 2.06B | 2.56B | 2.35B | 4.30B |
| Total Liabilities | 135M | 127M | 236M | 293M | 723M | 1.90B |
| Shareholders' Equity | 603M | 685M | 1.83B | 2.27B | 1.63B | 2.40B |
| Cash & Short-term Investments | 108M | 161M | 696M | 543M | 384M | 616M |
| Cash Flow | ||||||
| Operating Cash Flow | -147M | -224M | -351M | -557M | -898M | -1.54B |
| Capital Expenditure | 6.53M | 10.8M | 7.73M | 10.3M | 16.0M | 10.0M |
| Free Cash Flow | -154M | -235M | -358M | -568M | -914M | -1.55B |
| Ratios | ||||||
| ROE | -31.0% | -36.3% | -23.9% | -26.5% | -69.3% | -83.6% |
| ROA | -25.4% | -30.6% | -21.2% | -23.5% | -48.0% | -46.6% |
| Net Profit Margin | -636.6% | -703.0% | -3,768.3% | - | - | -762.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
REVOLUTION MED. DL-0001 dividends
REVOLUTION MED. DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns REVOLUTION MED. DL-0001
- Insiders 1.84%
- Institutions 98.16%
- Public & others 0.00%
- Shares outstanding 216M
- Free float 187M
REVOLUTION MED. DL-0001 company profile
- Company name
- REVOLUTION MED. DL-0001
- Ticker
- 42Z.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 883
- Fiscal year end
- December
- Address
- 700 Saginaw Drive, Redwood City, CA, United States, 94063
- Phone
- 650 481 6801
- Website
- revmed.com
About REVOLUTION MED. DL-0001
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
REVOLUTION MED. DL-0001 management
10- Dr. Mark A. Goldsmith M.D., Ph.D.CEO, President & Chairman · born 1962
- Mr. Jack AndersChief Financial Officer · born 1977
- Ms. Margaret A. Horn J.D.Chief Operating Officer · born 1963
- Mr. Jeffrey Cislini J.D.Senior VP, General Counsel & Corporate Secretary · born 1975
- Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.Senior Advisor · born 1961
- Dr. Martin D. Burke M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board
- Dr. Michael A. Fischbach Ph.D.Academic Co-Founder & Member of Scientific Advisory Board · born 1981
- Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory Board
- Mr. Walter Reiher Ph.D.Chief Information Officer
- Ms. Jan Smith Ph.D.Chief Scientific Officer